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See Article, pages 307–312Pruritus is the most prevalent symptom of cholestasis. Although
it is often under-appreciated by physicians, pruritus is more than
just an annoyance for patients with cholestasis. It reduces quality
of life and can lead to signiﬁcant disability. When very severe, it
may sometimes cause the patient to even contemplate suicide.
The pruritus of cholestasis is a difﬁcult clinical problem to man-
age and current medical treatments accepted as conventional are
unsatisfactory in a considerable proportion of cases, causing dis-
tress and exasperation to the patient as well as to the doctor [1].
Progress in the study of pruritus has been hampered by two
major problems. One is the subjective and multi-dimensional
nature of pruritus, which makes objective assessment difﬁcult.
The dimensions include: (1) a sensory signal (itch), (2) an emo-
tional reaction (discomfort, stress) and (3) a behavioural response
(scratching); the latter two components appear to be susceptible
to great individual variability and the former cannot yet be mea-
sured. The other major problem is the poorly deﬁned pathogene-
sis of pruritus in cholestasis. Peripherally acting pruritogens and
altered central neurotransmission have been implicated as caus-
ing pruritus in cholestasis. Unfortunately, the pruritogen(s) are
not yet identiﬁed although bile salts, progesterone metabolites,
histamine, and endogenous opioids have been proposed to
induce pruritus [2]. A new potential player in this ﬁeld has
recently emerged, namely lysophosphatidic acid (LPA) which is
a potent neuronal activator and is formed from lysophosphatidyl-
choline by the enzyme autotoxin (ATX) [3]. Nevertheless, and as a
consequence, current anti-pruritic treatments are mostly empir-
ical and not consistently effective.
Therapeutic efforts should always include an adequate ther-
apy of the underlying hepatobiliary disease, as it may result in
relief of pruritus. The speciﬁc treatment of pruritus can be cate-
gorized as (1) procedures aimed at the removal of pruritogens
from the body, including non-absorbable anion-exchange resins
which bind many hydrophobic substances in the intestinal
lumen, and invasive procedures such as hemodialysis, plasma-
pheresis, extracorporeal albumin dialysis (mainly the molecular
adsorbent recirculating system or MARS), nasobiliary drainage
or even surgical partial biliary diversion; (2) drugs aimed at alter-Journal of Hepatology 20
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modifying itch perception which is an intimately intertwined
process with that of pain [4]. Practice guidelines have been
recently provided by the European Association for the Study of
Liver Diseases (EASL) [5] and by the American Association for
the Study of Liver Diseases (AASLD) [6]. Consensual recommen-
dations have emerged. The ﬁrst line of treatment is the anion-
exchange resin, the best-known being cholestyramine, although
the evidence based to support its efﬁcacy is limited. This agent
(4 g up to four times daily) often gives rise to gastrointestinal dis-
turbance and is poorly tolerated in some patients but appears to
be effective in patients with mild pruritus. It needs to be spaced
away from any other oral medication by at least 4 h. The second
line of therapy is the antibiotic rifampicin and has a strong evi-
dence base. Rifampicin is an enzyme inducer and a pregnane X
receptor (PXR) agonist. The usual dose is 300 mg daily. Patients
do need to be monitored for complications such as hepatitis, hae-
molytic anemia and renal dysfunction, even though they are rare.
The third-line therapy is the opioid antagonists, given in very low
doses initially and increasing the dose as the patient is able to tol-
erate the symptoms typical of opiate withdrawal. Sertraline, a
serotonin re-uptake inhibitor, may be regarded as fourth-line
treatment. Patients resistant to the above agents can be treated
with drugs with anecdotal support or referred to specialized cen-
ters, where more invasive approaches should be considered.
Among these ones, nasobiliary drainage deserves a special atten-
tion in benign recurrent intra-hepatic cholestasis because it is
able to induce a fast and long-lasting remission [7]. Lastly, liver
transplantation should only be considered when all available
interventions listed above have proven ineffective after exclusion
of psychiatric co-morbidity that might contribute to the itch [8].
In this issue of the Journal, Pares et al. report on the use of
albumin dialysis in patients with resistant pruritus [9]. The so-
called MARS procedure is as an extracorporeal hemoﬁltration
system using an albumin-enriched dialysate to remove albu-
min-bound substances in patients with liver failure [10]. The
authors studied 20 patients with chronic cholestatic liver disease
or chronic liver graft rejection. Two MARS sessions were per-
formed in most patients (either one day apart or in consecutive
days). Pruritus dramatically decreased immediately after the pro-
cedure (by 72% as assessed by visual analog score) and partially
resumed after 30 days but its severity was still signiﬁcantly lower
as compared to baseline (by 51%). This improvement was10 vol. 53 j 228–229
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observed in all but one patient and was associated with a signif-
icant decrease in serum markers of cholestasis including bile
acids. The magnitude of pruritus improvement correlated nega-
tively with baseline serum bile acid and cholesterol levels. No
major side-effects were observed. Surprisingly, a number of
patients remained virtually free of pruritus after a prolonged fol-
low-up (up to 8.6 years).
The authors have to be congratulated for performing this
observational case series study that is the largest ever reported
on the use of MARS in patients with resistant pruritus. As a pla-
cebo effect cannot be ruled out, randomized placebo-controlled
trials are the best way to address therapeutic issues, especially
when the primary end-point is, at least in part, subjective. How-
ever, such trials are virtually unfeasible when an invasive proce-
dure is tested. Despite their obvious limitations, retrospective
non-randomized studies may provide useful information in this
context. Clearly, the tremendous improvement reported here
indicates that this procedure has to be considered in patients
with severe cholestasis and intractable pruritus. Furthermore, it
has recently been shown that albumin dialysis could be proposed
as an ‘‘out-patient” service for itch [11]. However further devel-
opment in technology are warranted to reduce the high costs
associated with MARS treatments.
Interestingly, the limitations of this work illustrate well the
difﬁculties inherent to studies dealing with the treatment of
resistant pruritus. First and generally speaking, the number of
patients with refractory pruritus is limited (only 20 patients were
included in 3 reference centers along several years). Secondly,
resistance to medical treatment should be clearly deﬁned; in
the present paper, no details were provided and, surprisingly, a
number of patients seemed to have only a moderate cholestasis
as reﬂected by normal bilirubin levels in half and relatively mild
increase of serum bile acids levels (mean = 40 lM). In addition,
among those with long-term follow-up available, only a minority
suffered from severe pruritus recurrence. Although there is no
strict correlation between the degree of cholestasis and the sever-
ity of pruritus, this is, in my experience, neither the biochemical
proﬁle nor the course usually observed in patients with ‘‘intracta-
ble” pruritus. Thirdly, pruritus severity should be assessed by the
same validated tool in the different participating centers. The cur-
rent recommended methodologies for measuring pruritus are a
visual analog score (VAS) or the more recent 5-D questionnaire
which is a multi-dimensional tool that encompasses the duration,
degree, disability, and distribution of pruritus [12]. An objective
assessment of itch through physical measurement of scratching
activity has been advocated as a more appropriate measure but,
in practice, is only a research tool. Fourthly, all extracorporeal
blood puriﬁcation techniques are directed towards elimination
of putative peripherally or centrally acting pruritogens that accu-
mulate in plasma and tissues of patients with cholestasis and
pruritus. However, the major pruritogen removed by these inter-
ventions has not been clearly deﬁned and there is currently no
validated serum marker of itch intensity although ATX activity
looks promising [13]. As a consequence, objective corroboration
of the symptomatic improvement is lacking. The authors focused
on the potential role of bile acids in the pathogenesis of pruritus.
However and as recently reviewed [14], the evidence for a key
role of bile acids is weak: itch is not seen in every patient with
liver disease and high serum levels of bile acids; despite ongoing
cholestasis and persistently elevated levels of bile acids, pruritus
improves in some patients; there is no established correlationJournal of Hepatology 201between severity of itch and concentrations of bile acids in circu-
lation and in skin; ﬁnally kinetics of bile acids do not correlate
with the course of pruritus in patients treated with extra corpo-
real blood puriﬁcation techniques or nasobiliary drainage.
In conclusion, albumin dialysis appears to have a real place in
the management of resistant pruritus. However, efﬁcacy is only
transient in most cases and, before using this sophisticated inva-
sive treatment modality that has a high cost and potential side-
effects, it is recommended to use a stepwise medical approach
(including optimized administration of the different drugs)
according to the current EASL clinical practice guidelines on the
management of cholestatic liver diseases. Thus, the indication
to use invasive procedures should be largely restricted and only
include patients with severe intractable pruritus resistant to
medical treatment that have a major reduction in quality of life,
and be mainly used as an alternative or bridge to liver transplan-
tation. Further clinical studies (including those evaluating the
optimal duration of MARS) should adopt strict and validated
methodologies. However, a major therapeutic breakthrough is
unlikely to occur until pruritogens are not identiﬁed. In this
regard, the help of Esculape (god of medicine) would be more
appropriate than that of Mars (god of war)!Conﬂicts of interest
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